FindTrial
Sign In

Real-world usage, effectiveness, and safety of Romosozumab in osteoporosis patients in Guangdong Province, China

Real-world usage, effectiveness, and safety of Romosozumab in osteoporosis patients in Guangdong Province, China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128279
Enrollment
Unknown
Registered
2026-07-17
Start date
2026-07-17
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe osteoporosis in postmenopausal women at high risk of fracture

Interventions

Romosozumab treatment group:None

Sponsors

Sun Yat-sen Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
50 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1.By the data cut-off date (EC submission), all patients who received at least one injection of Romosozumab in hospitals in Guangdong Province through the special medical zone policy of the Guangdong-Hong Kong-Macao Greater Bay Area will be included in this study.

Exclusion criteria

Exclusion criteria: 1.Not applicable.

Design outcomes

Primary

MeasureTime frame
Bone Mineral Density (BMD);—

Secondary

MeasureTime frame
VAS score;Overall incidence of adverse events after Romosozumab injection;Osteoporosis-related blood markers (including bone turnover markers such as P1NP, ß-CTX, N-MID, etc., and serum calcium, etc.);—

Countries

China

Contacts

Public ContactDing Yue

Sun Yat-sen Memorial Hospital

dingyue36@126.com+86 20 81332496

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026